Home > News > APP Announces FDA Acceptance of New Drug
May 10th, 2004
APP Announces FDA Acceptance of New Drug
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.
Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015
Nanoliposomes Help Efforts to Cure Bacterial Infections January 27th, 2015